Nektar Therapeutics (NKTR)

16.99
NASDAQ : Health Technology
Prev Close 16.98
Day Low/High 16.58 / 17.27
52 Wk Low/High 16.56 / 69.76
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 2.98B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Traders Are Aggressively Fading the Open

Traders Are Aggressively Fading the Open

But what will be most important is whether support stays strong and the buyers show interest in the afternoon.

Rev's Forum: Don't Just Sit There, Do Something!

Rev's Forum: Don't Just Sit There, Do Something!

Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

Here's how to trade six of the most active names on the market this afternoon.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

Biotech Premarket Movers: CytomX, Aevi, Esperion

Biotech Premarket Movers: CytomX, Aevi, Esperion

CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

Interesting NKTR Put And Call Options For March 17th

Interesting NKTR Put And Call Options For March 17th

Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

First Week of NKTR August 2017 Options Trading

First Week of NKTR August 2017 Options Trading

Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest Jumps 12.5% For NKTR

Short Interest Jumps 12.5% For NKTR

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing

Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing

Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum

Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum

The big issue is if the market can build on Friday's jobs good news.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Using My Metal Detector Amid Gold and Silver Strength

Using My Metal Detector Amid Gold and Silver Strength

Computer programming has found that buying bad-news dips is a consistent winner.

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate

Nektar Therapeutics (NKTR) Weak On High Volume Today

Nektar Therapeutics (NKTR) Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Novice Trade: Nektar Therapeutics

Novice Trade: Nektar Therapeutics

Plus an update on the Urban Outfitters trade from yesterday.

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) stock is declining on Wednesday afternoon despite posting better-than-expected 2015 fourth quarter results after yesterday’s closing bell.

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

General Motors, MetLife and Tesla: Doug Kass' Views

General Motors, MetLife and Tesla: Doug Kass' Views

Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase...

TheStreet Quant Rating: D (Sell)